After a decisive clinical outperformance that the broader market inexplicably sold off, Inhibrx Biosciences (NASDAQ: INBX) CEO deployed more than $3.6 million of personal capital to buy shares. With about 28% of the public float sold short and a major FDA approval date looming, this concentrated insider buying signals a high-probability valuation reset and sets the stage for a potential short squeeze.
Investors tracking clinical-stage biotechnology often look for discrepancies between pipeline progress and share price. When a business posts data nearly doubling the response rate of a standard-of-care oncology drug, the natural expectation is a sharp rally. Instead, Inhibrx Biosciences shares fell 17% over the following weeks.
